RE: info24 Jun 2020 00:09
Quickdraw great work, been doing alot of reading today and I would like to suggest a few very small tweaks if thats ok?
First, the GlobalCo licencing agreement will be on or before 14th August however its very likely they built in a buffer of ATLEAST the 2-3 weeks built in before when they planned to announce in April. But worst case scenario 0-1.5 months for the first item on your list.
Second Global Co get an option to take a favourable exclusive licence on AML after the end of the development agreement, but they dont have any rights or options regarding ALL that I can see, it looks like Hemogenyx have completely in-housed ALL CDX bi-specific antibody development which means there is no reporting restrictions on it and they are probably more likely to bring it to human trials, perhaps through trials and then given Vlad wants to help as many people as possible probably there will be a non-exclusive licencing model.
Finally, Hu-PHEC update and phase 1 I think will be alot sooner, I watched again this video:
https://www.biotech-capital.com/companies/news/311105/orgenesis-teams-up-with-hemogenyx-in-second-collaboration-to-push-cancer-cell-replacement-product-to-clinical-trials-11105.html
Around 4mins 20 it is discussed and they say they want to get to trials as soon as possible but it will be "atleast a couple of months" This was posted 5th November 2018. The update 31st December 2019 implies Phase 1 trials had not yet started but US and European patents had been issued and they were at advanced stages of discussions, I would be surprised if they are not in Phase 1 trials before end of year.
Side note - Hu-PHEC - I didnt fully appreciate what it was before.... Its not just blood cancer where this will be used... Its VERY early days, but they are talking about a source for any individuals own stem cells.... Baldness... Growing heart valves... repairing blindness...